Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Removal Of Tonsils And Adenoids Associated With Ongoing Benefits For Children With Breathing Problems During Sleep
Two and a half years after children with sleep-related breathing disorders had surgery to remove their tonsils and adenoids (glands in the back of the throat), they appear to sleep better than they did before the procedure but not as well as they did six months after, according to a report in the July issue of Archives of Otolaryngology-Head & Neck Surgery, one of the JAMA/Archives journals. Initial improvements in their behavior were maintained except when measured by an index of attention-deficit/hyperactivity disorder (ADHD) symptoms.
generic viagra online
South Africa Launches HIV/AIDS Vaccine Trial
"The first clinical trial of an HIV/AIDS vaccine designed and developed in South Africa was launched in Cape Town" Monday, the SAPA/The Times reports. The trial will seek to determine the immune response of HIV-negative people to two experimental vaccines -- SAAVI DNA-C2 and SAAVI MVA-C (7/20).
News of the day
BioLineRx Announces Positive Preliminary Results From The Phase I/II Trial Of BL-1040
BioLineRx Ltd. (TASE:BLRX), a clinical stage drug development company, today announced positive preliminary results from the ongoing phase I/II clinical trial designed to assess the safety and feasibility of BL-1040, the first injectable device designed to address cardiac remodeling, in 20- 30 patients at several sites in Germany and Belgium. To date, 15 patients were successfully treated with BL-1040 with no complications. Moreover, six months follow up results from the first 5 patients show BL-1040"s efficacy in preventing cardiac remodeling and preserving cardiac function.
Oncology

Donor Stem Cell Transplantation Associated With Survival Benefit For Patients With Leukemia

An analysis of previous studies indicates that allogeneic stem cell transplantation (SCT) (stem cells from a compatible donor) is associated with significant overall and relapse-free survival benefit among adult patients with intermediate- and poor-risk but not good-risk acute myeloid leukemia in first complete remission, compared with nonallogeneic SCT therapies, according to an article in the June 10 issue of JAMA. The optimal curative treatment of acute myeloid leukemia (AML) in first complete remission (CR1) is uncertain. While more than 70 percent of younger adult patients with newly diagnosed AML will enter a CR1 after initial (induction) chemotherapy, a substantial number subsequently experience disease relapse, according to background information in the article. "Allogeneic SCT after myeloablative conditioning [high-dose radiation and/or chemotherapy given to destroy normal and cancerous cells in the bone marrow prior to infusion of donor stem cells] is a curative treatment option for younger patients with AML in CR1. However, concerns regarding allogeneic SCT-related toxicity, and questions regarding its benefit, limit its use for patients who have attained an initial remission," the authors write. John Koreth, M.B.B.S., D.Phil., of the Dana Farber Cancer Institute, Boston, and colleagues conducted a meta-analysis to quantify relapse-free survival (RFS) and overall survival benefit of allogeneic SCT for AML in CR1 overall, and also for good-, intermediate-, and poor-risk AML. The researchers conducted a search for articles on trials evaluating allogeneic SCT vs. nonallogeneic SCT therapies (autologous [donor and recipient are the same person] SCT, consolidation chemotherapy, or both) for AML in CR1. The researchers identified 24 trials that met criteria for inclusion in the analysis, which included 6,007 patients (5,951 patients in RFS analyses and 5,606 patients in overall survival analyses); 3,638 patients were analyzed by cytogenetic (abnormalities in the composition of the chromosomes) risk (547, 2,499, and 592 with good-, intermediate-, and poor-risk AML, respectively). "Our primary finding is that the totality of the prospective trial data indicates statistically significant RFS and overall survival benefit with allogeneic SCT for adult AML in CR1. This conclusion is supported by a variety of sensitivity and subgroup analyses ò€¦. Additionally, our analyses indicate that allogeneic SCT benefit likely varies by AML cytogenetic risk. We document significant RFS and overall survival benefit for allogeneic SCT in intermediate- and poor-risk AML, and a lack of significant RFS or overall survival benefit for good-risk AML," the authors write. "While enrollment in therapeutic trials is to be encouraged, our findings provide evidence to guide clinical decision making and future trial design." JAMA 2009;301[22]:2349-2361. Journal of the American Medical Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009